Elevated Serum LL37 and Myeloperoxidase-DNA Complexes Predict the Progression of Diabetic Kidney Disease
Kidney Diseases · 12.06.2026 · 12 (1) · 734-747
DOI: 10.1159/000552478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Diseases, online erschienen am 12.06.2026. Verfasst von Pingping Ren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Predicting early progression of diabetic kidney disease (DKD) remains challenging. The neutrophil-derived peptide LL37 is implicated in kidney inflammation, yet its role and prognostic value in DKD remain unclear.
Methods
RNA sequencing dataset was analyzed to examine the expression of CAMP (encoding LL37) and myeloperoxidase (MPO) in peripheral blood from diabetic mellitus patients. A clinical cohort of 94 biopsy-proven DKD patients and 63 healthy controls (HCs) was established. Serum LL37 and MPO-DNA complexes were measured using enzyme-linked immunosorbent assay. The correlation between serum LL37 and MPO-DNA complex levels and kidney function was assessed and assessed their association with DKD progression using restricted cubic spline analysis and Cox proportional hazards regression models.
Results
Bioinformatics analysis revealed significantly elevated CAMP expression in DM patients, with strong neutrophil infiltration. In the clinical cohort, serum LL37 levels were significantly higher in DKD patients than in HC, showing discriminatory power for DKD diagnosis (AUC = 0.90, 95% CI: 0.85–0.96). Serum LL37 and MPO-DNA complex levels correlate with elevated serum creatinine and reduced eGFR. After a median follow-up of 39 months, 60 patients (63.83%) experienced renal progression events. After adjusting for confounding factors, elevated serum LL37 and MPO-DNA complex levels were independent risk factors for DKD progression (per Ln-transformed HRs: 2.290 [95% CI: 1.491–3.518] and 1.833 [95% CI: 1.261–2.664], respectively).
Conclusion
Elevated serum LL37 and MPO-DNA complex levels are independently associated with kidney disease progression in patients with DKD, and increased circulating LL37 may be closely linked to neutrophil activation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Jiangxi Hospital, The First Affiliated Hospital, Zhejiang University School of Medicine, Nanchang, China.
- Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Zitieren
APA
Ren, P., Cao, H., Wen, X., Feng, S., Wang, C., Wang, Y., Jiang, H., Fang, X., & Chen, J. (2026). Elevated Serum LL37 and Myeloperoxidase-DNA Complexes Predict the Progression of Diabetic Kidney Disease. Kidney Diseases, 12(1), 734-747. https://doi.org/10.1159/000552478
Vancouver
Ren P, Cao H, Wen X, Feng S, Wang C, Wang Y, et al. Elevated Serum LL37 and Myeloperoxidase-DNA Complexes Predict the Progression of Diabetic Kidney Disease. Kidney Diseases. 2026;12(1):734-747. doi:10.1159/000552478
BibTeX
@article{Ren2026,
author = {Ren, Pingping and Cao, Huiling and Wen, Xiaoli and Feng, Shi and Wang, Cuili and Wang, Yucheng and Jiang, Hong and Fang, Xiangdong and Chen, Jianghua},
title = {Elevated Serum LL37 and Myeloperoxidase-DNA Complexes Predict the Progression of Diabetic Kidney Disease},
journal = {Kidney Diseases},
year = {2026},
volume = {12},
number = {1},
pages = {734--747},
doi = {10.1159/000552478}
}
EUVIMED